Predict your next investment

Corporation
tarsus.com

See what CB Insights has to offer

Partners & Customers

4

About Tarsus

Tarsus is a business-to-business media group with interests in exhibitions, conferences, publishing, and online media. It is based in London, England.

Tarsus Headquarters Location

1 Metro Building, 1 Butterwick

London, England, W6 8DL,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tarsus News

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

Aug 11, 2022

Second Quarter 2022 Financial Results Second quarter net loss for 2022 was $5.7 million, compared to net income of $6.3 million for the same period in 2021 Second quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $15.3 million, compared to $22.0 million for the same period in 2021 Second quarter research and development expenses for 2022 were $9.6 million (inclusive of stock-based compensation of $1.0 million), compared to $7.2 million for the same period in 2021 Second quarter general and administrative expenses for 2022 were $10.4 million (inclusive of stock-based compensation of $2.5 million), compared to $6.8 million for the same period in 2021 As of June 30, 2022, cash and cash equivalents were $245.4 million About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial. Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the potential approval and commercialization of TP-03, the initiation of Phase 2 studies for Lyme disease prevention and the treatment of rosacea, cash runway expectations, the terms of the license agreement with LianBio, the ability of LianBio to commercialize TP-03 in the Greater China territory, the market size for TP-03 and TP-05, future events and Tarsus’ plans for and the anticipated benefits of its product candidates including TP-03, TP-04 and TP-05, the timing, objectives and results of the clinical trials, anticipated regulatory and development milestones and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus may need to obtain additional funding to complete the development and any commercialization of its product candidates, if approved; Tarsus is heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis; the COVID-19 pandemic may affect Tarsus’ ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt manufacturing and supply chain or have other adverse effects on Tarsus’ business and operations; even if TP-03, TP-04, TP-05, or any other product candidate that Tarsus develops receives marketing approval, Tarsus may not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis, MGD, rosacea, Lyme disease prevention, and/or other diseases or conditions targeted by Tarsus’ products; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus will need to develop and expand the company and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for Tarsus’ product candidates, particularly TP-03 for the treatment of Demodex blepharitis and MGD, TP-04 for the treatment of Rosacea, as well as TP-05 for the prevention of Lyme disease, have not been established with precision and may be smaller than estimated; the results of Tarsus’ earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus’ planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; and if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus’ competitors could develop and commercialize products similar or identical to Tarsus’ products. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2021 filed on March 14, 2022 and the most recent Form 10-Q quarterly filing filed with the SEC, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Media Contact:

Tarsus Acquisitions

6 Acquisitions

Tarsus acquired 6 companies. Their latest acquisition was FounderMade on December 17, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/17/2021

$99M

Acquired

1

10/21/2021

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2021

Subscribe to see more

$99M

Subscribe to see more

10

12/5/2016

Subscribe to see more

$99M

Subscribe to see more

10

5/22/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/17/2021

10/21/2021

7/15/2021

12/5/2016

5/22/2015

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Tarsus Partners & Customers

4 Partners and customers

Tarsus has 4 strategic partners and customers. Tarsus recently partnered with Times Aerospace on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/21/2021

Partner

United Kingdom

Tarsus Group Announces Partnership with Times Aerospace.

At its core the partnership will offer cutting-edge content , promotion opportunities and increased connections across the aerospace community and will be led by the current Times Aerospace team -- Mark Brown will continue as publisher and Alan Peaford as editor-in-chief .

1

2/5/2020

Partner

Subscribe to see more

Subscribe to see more

10

6/12/2014

Vendor

United Arab Emirates

Subscribe to see more

Subscribe to see more

10

11/21/2013

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/21/2021

2/5/2020

6/12/2014

11/21/2013

Type

Partner

Partner

Vendor

Partner

Business Partner

Country

United Kingdom

United Arab Emirates

United States

News Snippet

Tarsus Group Announces Partnership with Times Aerospace.

At its core the partnership will offer cutting-edge content , promotion opportunities and increased connections across the aerospace community and will be led by the current Times Aerospace team -- Mark Brown will continue as publisher and Alan Peaford as editor-in-chief .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Tarsus Team

2 Team Members

Tarsus has 2 team members, including current Executive Vice President, Rachel Wimberly.

Name

Work History

Title

Status

Rachel Wimberly

Variety, Reed Business Information, New York Times Digital, and CNN-News18

Executive Vice President

Current

Ashley Milton

Chief Financial Officer

Former

Name

Rachel Wimberly

Ashley Milton

Work History

Variety, Reed Business Information, New York Times Digital, and CNN-News18

Title

Executive Vice President

Chief Financial Officer

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.